Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes.

ABSTRACT:

Background

Markers of bone and extracellular matrix (ECM) remodeling may be associated with adverse outcomes in atherosclerotic cardiovascular disease. Podocan is a newly discovered ECM glycoprotein, previously not studied in a chest pain population. We wanted to study the association between Podocan levels on admission and the risk of adverse outcomes in a chest pain population with suspected acute coronary syndromes.

Methods

A total of 815 patients from the Risk markers in Acute Coronary Syndrome (RACS) trial with suspected coronary chest pain were followed for 7 years. Blood samples were taken immediately after inclusion and stored in the biobank. Associations between Podocan and endpoints were assessed with Cox proportional hazards analyses.

Results

The median adm

SUBMITTER: Andersen T 

PROVIDER: S-EPMC9163367 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature